NCT03344016Recruiting
Multicenter Pheochromocytoma and Paraganglioma Evaluation
Summary
Target population: Patients with (1) newly diagnosed or (2) past history of pheochromocytomas and paragangliomas (PPGL) or (3) carrier of genetic mutations in known PPGL susceptibility genes. International multicenter prospective cohort study with randomized intervention (special care follow-up vs. standard care follow-up). All patients will receive instructions about follow-up at the time point of study inclusion. Patients randomized to the standard care follow-up group will be advised to return annually for follow-up according to current routine practice (without active re-scheduling). In contrast, patients randomized to the special care follow-up group will also be advised to return annually for follow-up but these patients will be actively invited, re-scheduled and reminded by the centers to meet scheduled follow-up appointments.
Inclusion criteria
male and female patients (≥ 5 years of age), who fulfill one or more of the following criteria: (i) Patients with a newly diagnosed PPGL. (ii) Patients with a previous history of PPGLs. (iii) Carrier of genetic mutations known to predispose for the development of PPGLs. All subjects must have read, understood and signed the informed consent form, before inclusion into the study protocol. Signed parental consent must be obtained for children with suspected PPGLs who are enrolled in the study.
Exclusion criteria
• Patients with impaired mental capacity that precludes informed consent. • Pregnancy does not constitute criteria for exclusion from the protocol. However, in pregnant women no Clonidine testing, no PET scanning, MIBG scanning or contrast CT will be performed. • Patients at risk from injury from the MRI magnet due to implantable metal or who suffer from anxiety in enclosed spaces are excluded from MRI.
Contacts
The trial team's contact details are shown on request.
See the official trial record- Status
- Recruiting
- Phase
- No phase (N/A)
- Study type
- Interventional
- Countries
- Switzerland
- Sponsor
- Felix Beuschlein(Other)
- Protocol no.
- 742-16
- Conditions
- Pheochromocytoma, Paraganglioma
- Interventions
- Other
Treatments studied
- Contact by clinical center
Collaborators
Technische Universität Dresden, Wuerzburg University Hospital, University of Zurich, Radboud University Medical Center, Lübeck University Clinic, Ludwig-Maximilians - University of Munich
Locations · 1
- Zurich, SwitzerlandUniversity Hospital ZurichRecruiting at this site
In total, worldwide, the only site listed in the registry is recruiting.
Site status per the ClinicalTrials.gov registry (last update posted: July 9, 2020).
This status may have changed and says nothing about your eligibility: before taking any step, check with your oncologist or the site.
See also
Other versions
These results are indicative and do not replace medical advice — discuss them with your doctor.